Member Info for LordSnooty

to hope that, this being the final day in the tax year, our friendly seller might finally cease his relentless hitting of the bid once and for all?

that whoever is able to attend the weekend's presentation will endeavour to convey this board's sentiments regarding the present state of affairs; I myself will be practicing my sculling on the Thames, in preparation for the Henley Seniors Regatta.

the end of another riproaring week at FFWD. Prizewinners this week? Wednesday's mistaken RNS from 2017 takes first place, followed by, in joint second, yesterday evening's dummy-spitting megafest involving multiple contestants.
Roll on next week, what new delights await?

Or perhaps you'd enjoy Chico more..... https://youtu.be/amQ63EZfUMA

https://youtu.be/VKTT-sy0aLg

Second that emotion, Chilsworthy; such elementary slip-ups make them look like numpties.

Going begging at 9.8p, after that next offer is showing 10.25 right now.

ODONNELLS - I'm not sure Quint will be privy to the clinical details

Wrll f*ck 'em, I say. They have sold into every recovery rise we've attempted over the last year. Good riddance, if they are done selling. But we shall see.

All the good articles, the awards, the positive sentiments have failed so far to have any impact at all on the share price. A solid RNS that has a direct effect on the NAV is needed to get the ball rolling. What's it going to be?

Matador - I'm not looking to argue the issue, merely pointing out that the success rate for new drugs/delivery systems, especially with junior pharma, is very low, despite the factors you mention, and despite some making it as far as P3, only to fail at the final hurdle. However, no-one can say more, so I'll leave it at that, in the hope both for ourselves and for cancer sufferers that it proves a winner.

Having had some experience of holding junior pharma, I'd be very cautious about getting overenthusiastic about Intensity. Yes, it is looking good in the early stages, and yes, there is the potential for a left-field buyout or major stake being taken which would increase our holding's value incrementally over night. But it is still only in P1, which in clinical trial terms is barely off the starting blocks, and big pharma typically does not put money on the table until at least P2b, some way down the road yet.

!

Hope you're right, Mr Dog - it's been an arid and almost barren wait.

What a card you are, Chilsworthy, all this nonsense about fishing for the absolute bottom. Last time you missed it and it cost you a full penny more per share to panic buy in. Take care history doesn't repeat itself.

"Should of" Chillpots? "Should of"?

that's me done.

just now look like a Bed & Brexit.

The Dynamic Welly Company m'self.

Without news, looks like we might be headed to 9p again, in which case there'll be a last top-up opp for Snooty to bring holding to a nice round figure.